Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Rating of “Buy” from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $25.83.

A number of research analysts recently issued reports on the company. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 77,705 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $16.39, for a total transaction of $1,273,584.95. Following the completion of the sale, the general counsel now directly owns 125,785 shares in the company, valued at approximately $2,061,616.15. This trade represents a 38.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the sale, the chief executive officer now owns 331,017 shares of the company’s stock, valued at $5,273,100.81. The trade was a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,981 shares of company stock worth $7,814,333 in the last quarter. 11.59% of the stock is owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in CNTA. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC lifted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after buying an additional 4,952 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $162,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA opened at $16.63 on Friday. The business’s 50-day moving average price is $16.71 and its 200 day moving average price is $15.87. The firm has a market cap of $2.19 billion, a P/E ratio of -10.87 and a beta of 1.53. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.